23 Jan, EOD - Indian

SENSEX 76520.38 (0.15)

Nifty 50 23205.35 (0.22)

Nifty Bank 48589 (-0.28)

Nifty IT 43351.75 (1.79)

Nifty Midcap 100 54098.85 (1.86)

Nifty Next 50 63499.75 (1.01)

Nifty Pharma 22343.3 (1.40)

Nifty Smallcap 100 17364.55 (1.12)

23 Jan, EOD - Global

NIKKEI 225 39958.87 (0.79)

HANG SENG 19700.56 (-0.40)

S&P 6122.5 (-0.16)

LOGIN HERE

companylogoMax Healthcare Institute Ltd

You are Here : Home > Markets > CompanyInformation > Board Meeting
BSE Code : 543220 | NSE Symbol : MAXHEALTH | ISIN : INE027H01010 | Industry : Healthcare |


Board Meeting
Announcement Date Date Of Meeting Purpose Detail
30-Oct-2024 05-Nov-2024 Quarterly Results Max Healthcare Institute Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2024 inter alia to consider and approve unaudited standalone and consolidated financial results of the Company for the quarter and half year ended September 30 2024 Standalone and Consolidated Financial Results for quarter and half year ended September 30, 2024 (As Per BSE Announcement dated on 05.11.2024)
13-Sep-2024 13-Sep-2024 Others Outcome of Board Meeting
24-Jul-2024 01-Aug-2024 Quarterly Results Max Healthcare Institute Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/08/2024 inter alia to consider and approve unaudited standalone and consolidated financial results of the Company for the quarter ended June 30 2024 Standalone and Consolidated Financial Results for quarter ended June 30, 2024 Outcome of Board Meeting held on August 1, 2024 (As per BSE Announcement Dated on 01/08/2024)
16-May-2024 22-May-2024 Final Dividend Max Healthcare Institute Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2024 inter alia to consider and approve Financial Results and recommend Final Dividend if any Outcome of Board meeting held on May 22, 2024 (As Per BSE Announcement Dated on 22.05.2024)
19-Jan-2024 31-Jan-2024 Quarterly Results Max Healthcare Institute Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2024 inter alia to consider and approve unaudited standalone and consolidated financial results of the Company for the quarter and nine months ended December 31 2023. Standalone and Consolidated Financial Results for quarter and nine months ended December 31, 2023 Outcome of Board Meeting held on January 31, 2024 (As Per BSE Announcement dated on 31.01.2024)
27-Oct-2023 06-Nov-2023 Quarterly Results Max Healthcare Institute Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2023 inter alia to consider and approve unaudited standalone and consolidated financial results of the Company for the quarter and half year ended September 30 2023 Outcome of Board Meeting held on November 6, 2023 Standalone and Consolidated financial results for quarter and half year ended September 30, 2023 (As per BSE Announcement Dated on 06/11/2023)
28-Jul-2023 07-Aug-2023 Quarterly Results Max Healthcare Institute Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2023 inter alia to consider and approve unaudited standalone and consolidated financial results of the Company for the quarter ended June 30 2023 MAX HEALTHCARE INSTITUTE LIMITED has informed BSE about Board Meeting to be held on 07 Aug 2023 to consider financial statements for the period ended June 2023. Financial results. Standalone and Consolidated Financial results for Quarter ended June 30 2023. Board Meeting Outcome for meeting held on August 7, 2023 (As Per BSE Announcement Dated on 07.08.2023)
10-May-2023 16-May-2023 Accounts Max Healthcare Institute Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/05/2023 inter alia to consider and approve Financial Results and recommend Final Dividend if any. Board recommended final dividend of Re.1 /- per equity share (10% of face value of Rs.10 /- each), out of the profits of the financial year 2022-23, subject to approval of the members of the Company, which shall be paid/ dispatched within 30 days from the conclusion of the ensuing Annual General Meeting (As Per BSE Bulletin Dated on 16.05.2023) Outcome of Board Meeting for Quarter and Financial Year ended March 31, 2023 (As Per BSE Announcement dated on 16.05.2023) Appointment of Mr. Narayan K. Seshadri as an Additional Director (Non-Executive and Non-Independent) Newspaper Publication pertaining to Financial Results for the quarter and financial year ended March 31, 2023 (As Per BSE Announcement Dated on 17.05.2023)
25-Jan-2023 02-Feb-2023 Quarterly Results Quarterly Results Max Healthcare Institute Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/02/2023 ,inter alia, to consider and approve Proposal for Issue of Non-Convertible Debentures (As per BSE Announcement Dated on 30/01/2023) Financial results Board Meeting outcome We wish to inform that based on the recommendation of nomination & remuneration committee, the board of directors ('Board') of Max Healthcare Institute Limited ('Company') at its meeting held on February 2, 2023 have considered and approved the appointment of Mr. Dhiraj Aroraa as Company Secretary and Compliance Officer of the Company with effect from February 3, 2023. Further, Mr. Rakesh Kumar Kaushik, who was appointed as 'Interim Compliance Officer' by the Board will cease to be 'Interim Compliance Officer' with effect from the close of business hours on February 2, 2023. (As Per BSE Announcement Dated on 02.02.2023)
15-Dec-2022 15-Dec-2022 Others Max Healthcare Institute Limited has informed the Exchange about approval to partly finance the cost of Phase-1 expansion of bed capacity at Dr. Balabhai Nanavati Hospital, a managed healthcare facility ('BNH') and other maters. Corrigendum to the intimation submitted subsequent to the Board Meeting held on December 15, 2022 under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (As per BSE Announcement Dated on 16/12/2022)
21-Oct-2022 01-Nov-2022 Quarterly Results Max Healthcare Institute Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/11/2022 inter alia to consider and approve We wish to inform that a meeting of Board of Directors of the Company is scheduled to be held on Tuesday November 01 2022 inter alia to consider and approve the Unaudited (Consolidated and Standalone) Financial Results of the Company for the quarter and half year ended September 30 2022 (UFRs). Accordingly trading window for dealing in securities of the Company will be opened after 48 hours of the declaration of aforesaid UFRs. Outcome of Board Meeting (As Per BSE Announcement Dated on 01.11.2022)
31-Aug-2022 31-Aug-2022 Change in Directors (i) Appointment of Mr. Anil Bhatnagar (DIN: 09716726) as an Additional Director (Non-Executive, Non-Independent); (ii) the term of re-appointment of Mr. Abhay Soi (DIN: 00203597) as the Chairman and Managing Director ('CMD') has been revised to 5 (five) years w.e.f. June 19, 2023; (iii) Approval of Max Healthcare Institute Limited-Employee Stock Option Plan-2022 of the Company for eligible employees of the Company/ its subsidiary(ies) and holding company (if any, in future), subject to approval of shareholders at the ensuing AGM. (i) Appointment of Mr. Anil Bhatnagar (DIN: 09716726) as an Additional Director (Non-Executive, Non-Independent) and recommendation to the shareholders at the ensuing Annual General Meeting ('AGM'), his appointment as Non-Executive Non-Independent Director, liable to retire by rotation. (ii)
27-Jul-2022 10-Aug-2022 Quarterly Results Max Healthcare Institute Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2022 inter alia to consider and approve In relation to captioned subject and above referred intimation we wish to inform that a meeting of Board of Directors of the Company is scheduled to be held on Wednesday August 10 2022 inter alia to consider and approve the Unaudited (Consolidated and Standalone) Financial Results of the Company for the quarter ended June 30 2022 (UFRs). Outcome of the Board Meeting Held on August 10, 2022 Intimation of placing the matter before the Board of Directors w.r.t. penalty imposed by the Stock Exchanges (NSE and BSE) on delay in filing the disclosure relating to Related Party Transactions as per Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the 'Listing Regulations') (As Per BSE Announcement dated on 10.08.2022) (i) Appointment of Mr. Anil Bhatnagar (DIN: 09716726) as an Additional Director (Non-Executive, Non-Independent); (ii) the term of re-appointment of Mr. Abhay Soi (DIN: 00203597) as the Chairman and Managing Director ('CMD') has been revised to 5 (five) years w.e.f. June 19, 2023; (iii) Approval of Max Healthcare Institute Limited-Employee Stock Option Plan-2022 of the Company for eligible employees of the Company/ its subsidiary(ies) and holding company (if any, in future), subject to approval of shareholders at the ensuing AGM. (As Per BSE Announcement Dated on 31/08/2022)
18-May-2022 25-May-2022 Accounts Max Healthcare Institute Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2022 inter alia to consider and approve In relation to captioned subject and above referred intimation we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday May 25 2022 inter alia to consider and approve the Unaudited (Consolidated and Standalone) Financial Results for the quarter ended March 31 2022 and Audited (Consolidated and Standalone) Financial Results for the year ended March 31 2022. Accordingly trading window for dealing in securities of the Company will get open after 48 hours of the declaration of aforesaid financial statement. Outcome of Board Meeting - May 25, 2022 (As Per BSE Announcement Dated on 25.05.2022)
16-May-2022 16-May-2022 Scheme of Amalgamation Pursuant to Regulation 30 of SEBI LODR, 2015, we wish to inform you that the Board of Directors of Alps Hospital Limited ('ALPS') and Max Hospitals and Allied Services Limited ('MHASL') at their respective meetings held today i.e. May 16, 2022 have approved the Scheme of Amalgamation under the provisions of Sections 230 to 232 of the Companies Act, 2013 and relevant Rules made thereunder, for the merger of ALPS with MHASL
1 2 

Capital Market Publishers India Pvt. Ltd

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071, India.

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

The power of the database is harnessed by our fired-up reporters to generate interesting ideas. The reader-friendly presentation of the idea, supplemented by relevant data and information, can be accessed online through Capita Telefolio and Telefolio Gold. These ideas are used by individual investors as well as institutional investors to do further research and stay ahead.

Copyright @ Capital Market Publishers India Pvt.Ltd

Designed, Developed and maintained by CMOTS Infotech (ISO 9001:2015 Certified)

Site best viewed in Internet Explorer Edge ,   Google Chrome 115.0.5790.111 + ,   Mozilla Firefox 115.0.3 + ,   Opera 30.0+, Safari 16.4.1 +